Upcoming penny stock catalysts for June/July 2026 in Biotech and Pharma

A lot of biotech is sitting in the sweet spot right now. I did really well riding REPL from around $3, and OTLK's been good to me from $0.8. The one I'd add to that list is AKBA around $1.04. It's smaller and a lot riskier, but the setup is genuinely asymmetric. I'd start small, maybe 0.5% NAV, and scale toward 1.5% as it plays out.

Same lens I always use, market cap first. You're basically buying \~$230M of revenue for a \~$280M cap, with $162M of cash sitting against it, so more than half the market cap is just money in the bank. The \~$197M debt looks scary on paper but it overstates the real picture. The only hard fixed piece is a \~$52M term loan. The rest is revenue-linked royalty paper that self-amortizes off sales.

VRDN is the cleanest setup of the bunch. PDUFA for veligrotug in thyroid eye disease is June 30, so roughly 5 weeks out. Both Phase 3s (THRIVE and THRIVE-2) hit their primary and every secondary, including the first ever Phase 3 showing of diplopia resolution in chronic TED. They've got $762M cash on the balance sheet, and management says that funds them through profitability if both lead assets get approved. There's pipeline depth too: elegrobart (the sub-Q autoinjector) just printed positive Phase 3 data on REVEAL-1 and REVEAL-2, with the BLA targeted for Q1 '27. Field force is hired, supply chain's ready. Main risks are Tepezza being entrenched and some of this already being derisked into the price, but as small-cap biotech setups go, this is about as clean as it gets.

PALI is the one with real asymmetry. The Phase 1b PALI-2108 data in fibrostenotic Crohn's came in positive in March, and the sell-side coverage is unusually thick for something this early (Piper Sandler, Wolfe, Stifel, HC Wainwright all at Buy). Consensus PT is $18.50 against a $2 stock. But it's still pre Phase 2 efficacy and they'll need to raise capital. Real shot on goal, just size the position accordingly.